There are some reports indicating treatment benefit associated with HER3-directed antibody GSK2849330 in NSCLC,178 and pan-ErbB inhibitor afatinib in a range of tumor types, including invasive mucinous adenocarcinoma and non-mucinous adenocarcinoma of the lung, cholangiocarcinoma, pancreatic ductal adenocarcinoma, and colorectal cancer.3,173,179,180 In a phase II basket study, TAPUR (NCT02693535), four patients with NRG1 fusion-positive tumors were treated with afatinib. This evidence concerns the gene NRG1 and non-small cell lung carcinoma.